Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Betamethasone oral spray - Grace Therapeutics

Next Previous
Drug Profile

Betamethasone oral spray - Grace Therapeutics

Alternative Names: Betamethasone - Grace Therapeutics; GTX 102; GTX102 - Grace Therapeutics

Latest Information Update: 29 Oct 2024

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Grace Therapeutics
  • Class Analgesics; Anti-inflammatories; Antiallergics; Antiasthmatics; Eye disorder therapies; Fluorinated steroids; Glucocorticoids; Pregnadienetriols; Small molecules
  • Mechanism of Action Glucocorticoid receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Ataxia telangiectasia
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Suspended Ataxia telangiectasia

Most Recent Events

  • 25 Oct 2024 Acasti Pharma is now called Grace Therapeutics
  • 27 Sep 2024 Ultragenyx Pharmaceutical plans the phase III Aspire trial for Angelman Syndrome (In Children, In adolescents) (Lumbar puncture, Injection) (NCT06617429)
  • 12 Sep 2024 Betamethasone is available for licensing as of 12 September 2024. https://www.acasti.com/contact-us

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top